Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednesday, November 5, 2025, at 12:00 PM ET. The event will feature experts in their fields, Francisco J. Quintana, PhD (Harvard Medical School) and Brian Feagan, MD, FRCPC (Western Ontario), who will discuss the unmet needs and evolving treatment landscape in ulcerative colitis (UC) and the promise of targeting AhR to resolve inflammation and promote mucosal healing in this chronic inflammatory disease. Company management will also provide a scientific and translational overview of EQ504, Equillium’s potent oral, colon-targeted AhR modulator that selectively activates key anti-inflammatory and tissue-regenerative pathways. Presenters will review preclinica
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium (NASDAQ:EQ) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Equillium to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Equillium to Participate in Upcoming Investor ConferencesGlobeNewswire
- Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript [Seeking Alpha]Seeking Alpha
- Equillium to Participate in Upcoming Investor ConferencesGlobeNewswire
EQ
Earnings
- 3/27/25 - Beat
EQ
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 144
- 11/14/25 - Form SCHEDULE
- EQ's page on the SEC website